Skip to main content
Premium Trial:

Request an Annual Quote

Visible Genetics Puts Itself on the Block; Future Uncertain

For an updated version of this article, click here.


NEW YORK, May 30 - Visible Genetics said today it is looking to sell itself.


The company said that a sale would "include a modest premium" to its current share price. Shares in the Toronto-based tool company closed at $3.75 on the Nasdaq yesterday. Its current market cap hovers around $65 million.


"While VGI is committed to acting in the best interest of its shareholders, the timing and outcome of this process is uncertain," the company said.


The decision by Visible Genetics has caused it to postpone a conference call scheduled for this morning.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.